Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.47 |
| ▸ | LIPC | P11150 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019598 | 0.98 | PTGDR2 (0.58) | PTGDR2KDM1AKDM4EALDH1A1HPGD | |
| SCHEMBL420174 | 0.95 | PTGDR2 (0.54) | PTGDR2KDM1AKDM4EALDH1A1HPGD | |
| SCHEMBL421273 | 0.92 | KDM4E (0.56) | PTGDR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27903406 | 0.87 | PTGDR2 (0.55) | PTGDR2KDM1AKDM4EALDH1A1HPGD | |
| SCHEMBL3023005 | 0.83 | CFTR (0.56) | PTGDR2KDM1A | |
| SCHEMBL6910638 | 0.82 | PTGDR2 (0.50) | PTGDR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7030581 | 0.81 | MRGPRX4 (0.47) | PTGDR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7030578 | 0.81 | MRGPRX4 (0.47) | PTGDR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27486621 | 0.81 | PTGDR2 (0.48) | PTGDR2KDM4CMRGPRX4 | |
| SCHEMBL16449418 | 0.79 | EPHX2 (0.50) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| CN-102292320-B | Aroylamino-and heteroaroylamino-substituted piperidines as GLYT-1 inhibitors | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| CN-102292320-A | Aroylamino-and heteroaroylamino-substituted piperidines as GLYT-1 inhibitors | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | PTGDR2 400/4885KDM1A 1277/4885KDM4E 2562/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | PTGDR2 400/4885KDM1A 1277/4885KDM4E 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.